Table 1 Demographic, functional and clinical characteristics of CHR-P and Controls

Number of participants

60

134

Female participants, n (%)

42 (68.9)

93 (69.4)

1

χ² = 0.00

1.0

Age at baseline, median (range)

22 (18–32)

20 (16–34)

1

H = 6

0.01

Age at onset, median (range)

–

17 (4–31)

Years in education, median (range)

16 (12–24)

15 (8–26)

1

H = 127

<0.001

UK citizen, N (%)

28 (45.9)

97 (72.4)

1

χ² = 12

<0.001

GAF, median (range)

88 (67–97)

58 (21–95)

1

H = 32

<0.001

GF: Role, median (range)

9 (5–9)

8 (4–9)

1

H = 55

<0.001

GF: Social, median (range)

9 (7–9)

8 (5–9)

1

H = 67

<0.001

 No medication

60 (98.36)

68 (50.75)

1

χ² = 42

<0.001

 Anti-psychotic

0

2 (01.49)

1

χ² = 0.01

0.9

 Mood stabiliser

0

1 (0.75)

1

χ² = 0.00

1.0

 Anti-depressant

0

30 (22.39)

1

χ² = 15

<0.001

 Anti-convulsant

0

1 (0.75)

1

χ² = 0.00

1.0

 Other

1 (1.64)

13 (9.70)

1

χ² = 3

0.06

 Multiple

0

21 (15.67)

1

χ² = 8

0.005

 No diagnosis

57 (95.0)

21 (15.67)

1

χ² = 126

<0.001

 Anxiety disorder

2 (3.33)

89 (66.42)

1

χ² = 77

<0.001

 Mood disorders

0

86 (64.18)

1

χ² = 73

<0.001

 Eating disorders

0

13 (9.70)

1

χ² = 5

0.03

 Alcohol dependence/abuse

1 (1.67)

40 (29.85)

1

χ² = 18

<0.001

 Substance dependence/abuse

0

21 (15.67)

1

χ² = 10

0.001

 Suicidality

1 (1.67)

72 (53.73)

1

χ² = 49

<0.001

 No diagnosis

59 (98.33)

62 (46.27)